A case-control study of response to lamivudine therapy for 2 years in Japanese and Chinese patients chronically infected with hepatitis B virus of genotypes Bj, Ba and C

Hepatology Research

Volumn 35, Issue 2, 2006, Pages 127-134

  Orito, Etsuro ^a   Fujiwara, Kei ^a   Tanaka, Yasuhito ^a   Yuen, Man Fung ^b   Lai, Ching Lung ^b   Kato, Takanobu ^a   Sugauchi, Fuminaka ^a   Kusakabe, Atsunori ^a   Sata, Michio ^c   Okanoue, Takeshi ^d   Niitsuma, Hirofumi ^e   Sakugawa, Hiroshi ^f   Hasegawa, Izumi ^g   Mizokami, Masashi ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^e TOHOKU UNIVERSITY HOSPITAL   (Japan)

^f UNIVERSITY OF THE RYUKYUS   (Japan)

^g CHUKYO HOSPITAL   (Japan)

Author keywords

HBV genotype Ba, Bj, C; Lamivudine; Resistant mutation; Response to therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTIC ACID; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; METHIONINE; TYROSINE; VIRUS DNA;

ADULT; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CASE CONTROL STUDY; CHINESE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENDER; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NONHUMAN; PATIENT SELECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; STATISTICAL SIGNIFICANCE;

EID: 33646801638     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hepres.2006.03.005     Document Type: Article

References (33)

1. Lee W.M. Hepatitis B virus infection. N Engl J Med 337 (1997) 1733-1745
2. Okamoto H., Tsuda F., Sakugawa H., et al. Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes. J Gen Virol 69 (1988) 2575-2583
3. Stuyver L., Gendt S., Van Geyt C., et al. A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J Gen Virol 81 (2000) 67-74
4. Arauz-Ruiz P., Norder H., Robertson B.H., et al. Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America. J Gen Virol 83 (2002) 2059-2073
5. Lindh M., Andersson A.S., and Gusdal A. Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus large-scale analysis using a new genotyping method. J Infect Dis 175 (1997) 1285-1293
6. Kao J.H., Chen P.J., Lai M.Y., et al. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 118 (2000) 554-559
7. Orito E., Ichida T., Sakugawa H., et al. Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan. Hepatology 34 (2001) 590-594
8. Orito E., Mizokami M., Sakugawa H., et al. A case-control study for clinical and molecular biological differences between hepatitis B virus of genotypes B and C. Hepatology 33 (2001) 218-223
9. Miyakawa Y., and Mizokami M. Classifying hepatitis B virus genotypes. Intervirology 46 (2003) 329-338
10. Yuen M.F., Sablon E., Tanaka Y., et al. Epidemiological study of hepatitis B virus genotypes, core promoter and precore mutations of chronic hepatitis B infection in Hong Kong. J Hepatol 41 (2004) 119-125
11. Sugauchi F., Orito E., Ichida T., et al. Hepatitis B virus genotype B with or without recombination with genotype C over the precore region plus the core gene. J Virol 76 (2002) 5985-5992
12. Sugauchi F., Orito E., Ichida T., et al. Epidemiologic and virologic characteristics of hepatitis B virus genotype B having the recombination with genotype C. Gastroenterology 124 (2003) 925-932
13. Orito E., Sugauchi F., Tanaka Y., et al. Differences of hepatocellular carcinoma patients with hepatitis B virus genotypes of Ba, Bj or C in Japan. Intervirology 48 (2005) 239-245
14. Lai C.L., Chien R.N., Leung N.W.Y., et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 339 (1998) 61-68
15. Chayama K., Suzuki Y., Kobayashi M., et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 27 (1998) 1711-1716
16. Mizokami M., Nakano T., Orito E., et al. Hepatitis B virus genotype assignment using restriction fragment length polymorphism patterns. FEBS Lett 450 (1999) 66-71
17. Ohba K., Mizokami M., Ohno T., et al. Relationships between serotypes and genotypes of Hepatitis B virus genetic classification. Virus Res 39 (1995) 25-34
18. Chan H.I., Hussain M., and Lok A.S. Different hepatitis B virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion. Hepatology 29 (1999) 976-984
19. Lok A.S. Natural history and control of perinatally acquired hepatitis B virus infection. Dig Dis 10 (1992) 46-52
20. Lin H.H., Chen P.J., Chen D.S., et al. Postpartum subsidence of hepatitis B viral replication in HBeAg-positive carrier mothers. J Med Virol 29 (1989) 1-6
21. Chien R.N., Yeh C.T., Tsai S.L., et al. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology 38 (2003) 1267-1273
22. Yuen M.F., Wong D.K., Sablon E., et al. Hepatitis B virus genotypes B and C do not affect the antiviral response to lamivudine. Antivir Ther 8 (2003) 531-534
23. Suzuki F., Tsubota A., Arase Y., et al. Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan. Intervirology 46 (2003) 182-189
24. Akuta N., Suzuki F., Kobayashi M., et al. The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment. J Hepatol 38 (2003) 315-321
25. Zollner B., Petersen J., Puchhammer-Stockl E., et al. Viral features of lamivudine resistant hepatitis B genotypes A and D. Hepatology 39 (2004) 42-50
26. Moskovitz D.N., Osiowy C., Giles E., et al. Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance. J Viral Hepat 12 (2005) 398-404
27. Lo C.M., Cheung C.K., Lau G.K., et al. Significance of hepatitis B virus genotype in liver transplantation for chronic hepatitis B. Am J Transplant 5 (2005) 1893-1900
28. Leung N.W.Y., Lai C.L., Chang T.T., et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 33 (2001) 1527-1532
29. Perrillo R.P., Lai C.L., Liaw Y.F., et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 36 (2002) 186-194
30. Laras A., Koskinas J., Avgidis K., et al. Incidence and clinical significance of hepatitis B virus precore gene translation initiation mutations in e antigen-negative patients. J Viral Hepat 5 (1998) 241-248
31. Lau D.T.Y., Khokhar M.F., Doo E., et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 32 (2000) 828-834
32. Chang M.L., Chien R.N., Yeh C.T., et al. Virus and transaminase levels determine the emergence of drug resistance during long-term lamivudine therapy in chronic hepatitis B. J Hepatol 43 (2005) 72-77
33. Tanaka Y., Yeo A.E.T., Orito E., et al. Prognostic indicators of breakthrough hepatitis during lamivudine monotherapy for chronic hepatitis B virus infection. J Gastroenterol 39 (2004) 769-775